Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Macleod gets CDSCO Nod to Study Sitagliptin, Metformin & Glimepiride FDC
Details : Sitagliptin, metformin and glimepiride fixed dose combination is being evaluated for the treatment of patients with type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : CytoDyn
Deal Size : Undisclosed
Deal Type : Agreement
Details : Leronlimab is a viral-entry inhibitor in HIV/AIDS. This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance.
Product Name : PRO 140
Product Type : Large molecule
Upfront Cash : Undisclosed
May 13, 2021
Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : CytoDyn
Deal Size : Undisclosed
Deal Type : Agreement